The Bangalore Hospital Trials

The Bangalore Hospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

FRASSINETI, Giovanni

OINC, NCT04480268: PAXG Out in the Country

Recruiting

175

Europe

PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy

IRCCS San Raffaele

Pancreatic Ductal Adenocarcinoma

01/22

01/26

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting

2/3

600

Europe, US, RoW

SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo

Panbela Therapeutics, Inc.

Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

08/26

01/27

ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting

477

Europe

5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib

Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.

Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer

10/25

12/27

RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting

N/A

3000

Europe

Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.

Solid Tumours in Advanced Stages

10/26

Azevedo, Sergio de

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed

571

Europe, Canada, US, RoW

NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel

NovoCure Ltd.

Pancreas Adenocarcinoma

10/24

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen Inc., Merck Sharp & Dohme LLC

Colorectal Neoplasms

08/25

04/28

NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

Europe, Japan, US, RoW

TAK-981, Pembrolizumab

Takeda, Takeda Development Center Americas, Inc.

Advanced or Metastatic Solid Tumors

11/25

Slingerland, Marije

OMAMA, NCT05216328: Prevention of Opioid-induced Constipation in Patients With Advanced Cancer

Recruiting

330

Europe

Macrogol Only Product in Oral Dose Form, Macrogol/electrolytes, Magnesium hydroxide 724mg, Magnesiumoxide

Amsterdam UMC, location VUmc, Leiden University Medical Center, University Medical Center Groningen, Radboud University Medical Center, Erasmus Medical Center, Spaarne Gasthuis, Rijnstate Hospital, Jeroen Bosch Ziekenhuis, Flevoziekenhuis, Martini Hospital Groningen, Haaglanden Medical Centre, Universitiy Medical Centre Utrecht UMCU The Netherlands, Groene Hart Ziekenhuis, Bernhoven Hospital, Isala, Antoni van Leeuwenhoekziekenhuis (AVL) Amsterdam

Constipation, Opioid-Induced

12/25

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

Carneiro, Filipa

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

Motola, Daniel

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

Krishnappa, Rajeev

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

Mazza, Elena

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

PROTECT, NCT05055648: PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

Recruiting

396

Europe

Photon Radiotherapy, Proton Radiotherapy, Proton Therapy

University of Aarhus, University of Leeds, KU Leuven, University College, London, Aarhus University Hospital, Technische Universität Dresden, Academisch Ziekenhuis Groningen, CNAO National Center of Oncological Hadrontherapy, Agenzia Nazionale per i Servizi Sanitari Regionali, Centre Antoine Lacassagne, Centre Leon Berard, Institut Curie, Maastro Clinic, The Netherlands, University College London Hospitals, The Christie NHS Foundation Trust, Paul Scherrer Institut, Center for Proton Therapy, HollandPTC, IBA worldwide, Varian- A Siemens Healthineer Company

Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy

12/27

12/32

Rosas, Vanessa

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26



	Diseases Companies Products Productz Mechanisms of Action Sites